BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Castagnoli L, Ladomery M, Tagliabue E, Pupa SM. The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers? Cancers (Basel) 2019;11:E902. [PMID: 31261614 DOI: 10.3390/cancers11070902] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Veiga DFT, Nesta A, Zhao Y, Mays AD, Huynh R, Rossi R, Wu TC, Palucka K, Anczukow O, Beck CR, Banchereau J. A comprehensive long-read isoform analysis platform and sequencing resource for breast cancer. Sci Adv 2022;8:eabg6711. [PMID: 35044822 DOI: 10.1126/sciadv.abg6711] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
2 Díaz-Rodríguez E, Gandullo-Sánchez L, Ocaña A, Pandiella A. Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs. Cancers (Basel) 2021;14:154. [PMID: 35008318 DOI: 10.3390/cancers14010154] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
3 Marima R, Francies FZ, Hull R, Molefi T, Oyomno M, Khanyile R, Mbatha S, Mabongo M, Owen Bates D, Dlamini Z. MicroRNA and Alternative mRNA Splicing Events in Cancer Drug Response/Resistance: Potent Therapeutic Targets. Biomedicines 2021;9:1818. [PMID: 34944633 DOI: 10.3390/biomedicines9121818] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Pupa SM, Ligorio F, Cancila V, Franceschini A, Tripodo C, Vernieri C, Castagnoli L. HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness. Cancers (Basel) 2021;13:4778. [PMID: 34638263 DOI: 10.3390/cancers13194778] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
5 Mehterov N, Kazakova M, Sbirkov Y, Vladimirov B, Belev N, Yaneva G, Todorova K, Hayrabedyan S, Sarafian V. Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy. Genes (Basel) 2021;12:1085. [PMID: 34356101 DOI: 10.3390/genes12071085] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Torres-Martinez Z, Delgado Y, Ferrer-Acosta Y, Suarez-Arroyo IJ, Joaquín-Ovalle FM, Delinois LJ, Griebenow K. Key genes and drug delivery systems to improve the efficiency of chemotherapy. Cancer Drug Resist 2021;4:163-91. [PMID: 34142021 DOI: 10.20517/cdr.2020.64] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Gameiro A, Almeida F, Nascimento C, Correia J, Ferreira F. Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma. Pharmaceutics 2021;13:346. [PMID: 33800900 DOI: 10.3390/pharmaceutics13030346] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Leal JL, Solomon B, John T. Finding chinks in the osimertinib resistance armor. Transl Lung Cancer Res 2020;9:2173-7. [PMID: 33209638 DOI: 10.21037/tlcr-20-579] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Volpari T, De Santis F, Bracken AP, Pupa SM, Buschbeck M, Wegner A, Di Cosimo S, Lisanti MP, Dotti G, Massaia M, Pruneri G, Anichini A, Fortunato O, De Braud F, Del Vecchio M, Di Nicola M. Anticancer innovative therapy: Highlights from the ninth annual meeting. Cytokine Growth Factor Rev 2020;51:1-9. [PMID: 31862236 DOI: 10.1016/j.cytogfr.2019.12.002] [Reference Citation Analysis]